Quantcast

Industry news that matters to you.  Learn more

Boston Microfluidics Contracts Affinity Life Sciences for Immunoassay Development and Protein Chemistry Services

Reading time: 2 minutes

Boston Microfluidics, Inc. (BMF), a developer of a novel Point-of-Care (POC) device, and Affinity Life Sciences, Inc., a contract research and manufacturing organization specializing in biomarker assay development and protein chemistry services, have partnered to develop immunoassays and chemistry components related to Boston Microfluidics’ POC device.

Boston Microfluidics, Inc. is a developer of a novel biomarker detection device, which provides portability and simplicity of use. BMF has contracted Affinity to develop biomarker assays in a microplate format which will be used as a model for transfer of these biomarkers to BMF’s POC device. The development of model ELISA tests, conjugates, and assay components by Affinity will allow BMF to evaluate these biomarker test components in their POC device. BMF’s current POC device can provide qualitative results in less than 1 minute, drastically reducing the time of a classical ELISA test.

Brandon Johnson, President of Boston Microfluidics is excited about the progress of these projects, “Affinity provides additional and independent resources for the development of biomarker assays and components necessary for our release of new and unique POC product lines. The quality and on-time service provided by Affinity has been critical for us to meet our investor’s deadlines and commitments. Affinity has demonstrated the dedication and adaptability necessary when working on such customized projects. Their help and expertise has been invaluable.”

“Affinity has worked with numerous platforms such as microplates, magnetic and latex beads, and multiplex systems and is pleased to have the opportunity to work with Boston Microfluidics, expanding our services into the POC industry,” said Tod Gavron, President of Affinity Life Sciences. “Seeing the successful transfer of developed assays, conjugations, and unique formulations to a POC device is exciting for all of us. We are confident that BMF’s unique product line will be a success in the marketplace.”

Source: PR.com